Interpace Biosciences, Inc. (IDXG)
USD 2.41
(-9.06%)
USD 2.41
(-9.06%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.78 Million | -7.69 Million | -8.71 Million | -14.57 Million | -18.95 Million | -8.67 Million |
| Net Income | 1.11 Million | -21.95 Million | -14.94 Million | -26.45 Million | -26.72 Million | -12.18 Million |
| Depreciation & Amortization | 1.02 Million | 2.56 Million | 5.37 Million | 5.5 Million | 4.18 Million | 3.46 Million |
| Deferred income taxes | -3.22 Million | -93 Thousand | 38 Thousand | 37 Thousand | 18 Thousand | -1.9 Million |
| Stock-based compensation | 630 Thousand | 1.3 Million | 1.36 Million | 2.24 Million | 1.53 Million | 2.27 Million |
| Change in working capital | -83 Thousand | -3.04 Million | -1.13 Million | 5.22 Million | -2.08 Million | -3.83 Million |
| Other non-cash items | 4.32 Million | 13.54 Million | 575 Thousand | -1.08 Million | 4.11 Million | 3.51 Million |
| Investing Cash Flow | -87 Thousand | 6.2 Million | -315 Thousand | -1.57 Million | -13.94 Million | -449 Thousand |
| Investments in PPE | -470 Thousand | -322 Thousand | -354 Thousand | -1.57 Million | -131 Thousand | -449 Thousand |
| Acquisitions | 383 Thousand | 6.52 Million | 39 Thousand | - | -13.82 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 383 Thousand | 6.52 Million | 39 Thousand | - | 13 Thousand | - |
| Financing Cash Flow | -5.03 Million | 3 Million | 8.97 Million | 16.6 Million | 29.15 Million | -9000.00 |
| Debt repayment | -5 Million | -3 Million | -7.92 Million | -3 Million | -6.02 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -32 Thousand | -108 Thousand | - | -52 Thousand | -41 Thousand | -9000.00 |
| Common Stock Issuance | - | 108 Thousand | 335 Thousand | 434 Thousand | 6.47 Million | - |
| Other Financing Activities | -2.5 Million | 9 Million | 16.56 Million | 19.22 Million | 28.74 Million | -9000.00 |
| Accounts receivables | 49 Thousand | -133 Thousand | 2.14 Million | 1.72 Million | -961 Thousand | -3.54 Million |
| Accounts payables | 489 Thousand | -735 Thousand | -1.81 Million | -198 Thousand | -835 Thousand | 668 Thousand |
| Inventory | - | - | - | - | -730 Thousand | -873 Thousand |
| Other working capital | -621 Thousand | -2.18 Million | -1.46 Million | 3.7 Million | 443 Thousand | -82 Thousand |
| Cash at beginning of period | 5.32 Million | 3.31 Million | 3.37 Million | 2.32 Million | 6.06 Million | 15.19 Million |
| Cash at end of period | 3.49 Million | 4.82 Million | 3.31 Million | 2.77 Million | 2.32 Million | 6.06 Million |
| Capital Expenditure | -470 Thousand | -322 Thousand | -354 Thousand | -1.57 Million | -131 Thousand | -449 Thousand |
| Effect of forex changes on cash | -500 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | -1.83 Million | 1.51 Million | -58 Thousand | 451 Thousand | -3.74 Million | -9.13 Million |
| Free Cash Flow | 3.31 Million | -8.01 Million | -9.07 Million | -16.15 Million | -19.08 Million | -9.12 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 2.13 Million | 572 Thousand | 813 Thousand | 1.11 Million | -528 Thousand | 175 Thousand |
| Depreciation & Amortization | 188 Thousand | 160 Thousand | 45 Thousand | 1.02 Million | 240 Thousand | 358 Thousand |
| Deferred income taxes | - | - | -111 Thousand | -3.22 Million | -314.99 Thousand | - |
| Stock-based compensation | 53 Thousand | 79 Thousand | 129 Thousand | 630 Thousand | 152 Thousand | 157 Thousand |
| Change in working capital | -853 Thousand | -808 Thousand | -831 Thousand | -83 Thousand | 1.02 Million | -499 Thousand |
| Other non-cash items | 1.34 Million | 563 Thousand | 1.09 Million | 4.32 Million | 527 Thousand | 220 Thousand |
| Investing Cash Flow | -197 Thousand | -28 Thousand | -142 Thousand | -87 Thousand | 348 Thousand | -228 Thousand |
| Investments in PPE | -197 Thousand | -28 Thousand | -142 Thousand | -470 Thousand | -152 Thousand | -111 Thousand |
| Acquisitions | - | - | -117 Thousand | 383 Thousand | 500 Thousand | -117 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -225 Thousand | - | 117 Thousand | 383 Thousand | 500 Thousand | -117 Thousand |
| Financing Cash Flow | -2 Million | -600 Thousand | -2.53 Million | -5.03 Million | -1.5 Million | -700 Thousand |
| Debt repayment | -2 Million | -600 Thousand | -2.5 Million | -5 Million | -1.5 Million | -700 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -32 Thousand | -32 Thousand | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -2 Million | -600 Thousand | -2.5 Million | -2.5 Million | -1.5 Million | -700 Thousand |
| Accounts receivables | -1.2 Million | -49 Thousand | -153 Thousand | 49 Thousand | 699 Thousand | -814 Thousand |
| Accounts payables | 163 Thousand | -176 Thousand | 261 Thousand | 489 Thousand | -382 Thousand | 78 Thousand |
| Inventory | - | - | 1.00 | - | -1.00 | - |
| Other working capital | 184 Thousand | -583 Thousand | -939 Thousand | -621 Thousand | 712 Thousand | 237 Thousand |
| Cash at beginning of period | 2.81 Million | 3.49 Million | 5.03 Million | 5.32 Million | 5.57 Million | 5.59 Million |
| Cash at end of period | 2.01 Million | 2.81 Million | 3.49 Million | 3.49 Million | 5.03 Million | 5.07 Million |
| Capital Expenditure | -197 Thousand | -28 Thousand | -142 Thousand | -470 Thousand | -152 Thousand | -111 Thousand |
| Effect of forex changes on cash | - | - | -1.03 Million | -500 Thousand | - | 1.03 Million |
| Net cash flow / Change in cash | -793 Thousand | -686 Thousand | -1.53 Million | -1.83 Million | -547 Thousand | -517 Thousand |
| Free Cash Flow | 1.2 Million | -86 Thousand | 998 Thousand | 3.31 Million | 953 Thousand | 300 Thousand |
ANZGY
NPK
RGPMF
DATS
STOVEKRAFT
600673